TY - JOUR
T1 - Management of 'In-Field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy
AU - Cante, Domenico
AU - La Porta, Maria Rosa
AU - Franco, Pierfrancesco
AU - Sciacero, Piera
AU - Girelli, Giuseppe Franco
AU - Marra, Annamaria
AU - Numico, Gianmauro
AU - Denaro, Nerina
AU - Russi, Elvio Grazioso
AU - Ricardi, Umberto
PY - 2013/11
Y1 - 2013/11
N2 - It is well known that the cetuximab (Cet) epidermal growth factor receptor (EGFR) antibody enhances the sensitivity of tumour cells to radiation, and it is likely that the concurrent administration of Cet and radiotherapy (RT) results in some degree of interplay between the effects of the individual agents on the skin and in the exacerbation of reactions normally seen with these individual agents. In this paper, we present a concise review of Cet/RT-related skin toxicity, focusing on mechanisms and pathogenesis, clinical presentation and scoring systems and, finally, therapeutic management.
AB - It is well known that the cetuximab (Cet) epidermal growth factor receptor (EGFR) antibody enhances the sensitivity of tumour cells to radiation, and it is likely that the concurrent administration of Cet and radiotherapy (RT) results in some degree of interplay between the effects of the individual agents on the skin and in the exacerbation of reactions normally seen with these individual agents. In this paper, we present a concise review of Cet/RT-related skin toxicity, focusing on mechanisms and pathogenesis, clinical presentation and scoring systems and, finally, therapeutic management.
KW - Cetuximab
KW - Dermatitis
KW - Epidermal growth factor receptor
KW - Head and neck cancer
KW - Radiation-induced toxicity
UR - http://www.scopus.com/inward/record.url?scp=84886742539&partnerID=8YFLogxK
U2 - 10.1159/000355579
DO - 10.1159/000355579
M3 - Review article
SN - 0030-2414
VL - 85
SP - 257
EP - 261
JO - Oncology
JF - Oncology
IS - 5
ER -
